Immuneering Corp
IMRX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001790340
No open-market purchases or sales by Immuneering Corp insiders were filed in the last 90 days; 111 institutions reported holding it in 13F filings for Q2 2026, worth $171.6M in total; no superinvestor holds it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Oct 30, 2026, 1:20 AM ET
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 6, 2026 | Mar 20, 2025 | Mar 1, 2024 | Mar 6, 2023 | Mar 10, 2022 |
| Revenue | – | – | $0 | $317.0K | $2.08M |
| Cost of revenue | – | – | $0 | $158.1K | $1.15M |
| Gross profit | – | – | $0 | $158.8K | $926.9K |
| Operating expenses | $59.4M | $64.1M | $58.4M | $51.9M | $34.8M |
| Research and development | $42.0M | $48.0M | $41.6M | $36.3M | $26.5M |
| Selling, general and administrative | $17.3M | $16.1M | $16.8M | $15.6M | $8.27M |
| Operating income | -$59.4M | -$64.1M | -$58.4M | -$51.7M | -$33.9M |
| Income tax | $0 | – | – | – | -$307.5K |
| Net income | -$56.0M | -$61.0M | -$53.5M | -$50.5M | -$33.5M |
| EPS, basic | $-1.27 | $-2.04 | $-1.88 | $-1.91 | $-2.46 |
| EPS, diluted | $-1.27 | $-2.04 | $-1.88 | $-1.90 | $-2.46 |
| Weighted shares, basic | 44.0M | 30.0M | 28.4M | 26.4M | 13.6M |
| Weighted shares, diluted | 44.0M | 30.0M | 28.4M | 26.4M | 13.6M |
| Margins and growth | |||||
| Gross margin | – | – | – | 50.1% | 44.6% |
| Operating margin | – | – | – | -16325.8% | -1629.2% |
| Net margin | – | – | – | -15937.3% | -1612.3% |
| Revenue growth, year over year | – | – | −100.0% | −84.8% | – |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 6, 2026 | Mar 20, 2025 | Mar 1, 2024 | Mar 6, 2023 | Mar 10, 2022 |
| Cash and equivalents | $128.6M | $36.1M | $59.4M | $72.6M | $74.9M |
| Short-term investments | – | – | – | $32.9M | $74.3M |
| Accounts receivable | – | – | $0 | $12.4K | $246.0K |
| Total current assets | $176.2M | $39.6M | $89.1M | $108.7M | $152.3M |
| Property, plant and equipment | $938.5K | $1.12M | $1.40M | $1.37M | $807.2K |
| Goodwill | $6.69M | $6.69M | $6.69M | $6.69M | $6.70M |
| Intangible assets | $321.1K | $350.4K | $379.7K | $408.9K | $439.0K |
| Total assets | $232.0M | $52.7M | $102.6M | $122.4M | $166.7M |
| Accounts payable | $1.54M | $1.96M | $2.11M | $3.15M | $1.39M |
| Total current liabilities | $10.1M | $7.50M | $7.85M | $8.05M | $5.63M |
| Total liabilities | $13.5M | $11.3M | $12.0M | $12.5M | $10.7M |
| Shareholders' equity | $218.5M | $41.4M | $90.6M | $109.9M | $156.0M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 6, 2026 | Mar 20, 2025 | Mar 1, 2024 | Mar 6, 2023 | Mar 10, 2022 |
| Operating cash flow | -$45.3M | -$55.0M | -$49.0M | -$44.1M | -$30.9M |
| Capital expenditures | $142.2K | $84.9K | $342.7K | $742.5K | $60.8K |
| Free cash flow | -$45.5M | -$55.1M | -$49.3M | -$44.8M | -$30.9M |
| Depreciation and amortization | $324.5K | $355.8K | – | – | – |
| Stock-based compensation | $6.31M | $6.50M | $5.73M | $4.06M | $1.80M |
| Investing cash flow | -$88.7M | $26.4M | $7.30M | $41.8M | -$75.6M |
| Financing cash flow | $226.6M | $5.30M | $28.4M | $19.0K | $144.3M |
| Net change in cash | $92.5M | -$23.3M | -$13.2M | -$2.25M | $37.8M |
| Ratio | |||||
| Stock-based compensation, % of revenue | – | – | – | 1282.4% | 86.7% |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Sep 3, 2021 | 25.9M | – | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.